Articles From: Seattle Genetics and Bristol-Myers Squibb Announce Clinical Collaboration to Evaluate Combination of Adcetris® (Brentuximab Vedotin) and Opdivo® (Nivolumab) in Hematologic Malignancies to SEC Probes CVR Disclosure During Takeover--Update 1


2015/1/12
Seattle Genetics, Inc. (Nasdaq:SGEN) and Bristol-Myers Squibb Company (NYSE:BMY) today announced that the companies have entered into a clinical trial collaboration agreement to evaluate the investigational combination of Seattle Genetics’ antibody-drug conjugate (ADC) Adcetris (brentuximab vedotin) and Bristol-Myers Squibb’s immunotherapy Opdivo (nivolumab) in two planned Phase 1/2 clinical trials.
Sign-up for Seattle Genetics and Bristol-Myers Squibb Announce Clinical Collaboration to Evaluate Combination of Adcetris® (Brentuximab Vedotin) and Opdivo® (Nivolumab) in Hematologic Malignancies investment picks
2014/12/7
Seattle Genetics, Inc. (Nasdaq: SGEN) and Takeda Pharmaceutical Company Limited (TSE:4502) today announced four-year overall survival (OS) data from the ADCETRIS (brentuximab vedotin) pivotal Phase 2 clinical trial in relapsed or refractory systemic anaplastic large cell lymphoma (ALCL). ADCETRIS is an antibody-drug conjugate (ADC) directed to CD30, which is expressed in classical Hodgkin lymphoma (HL) and systemic ALCL, a type of T-cell lymphoma.
Sign-up for Seattle Genetics and Takeda Announce Four-Year Survival Data from ADCETRIS® (Brentuximab Vedotin) Pivotal Trial in Relapsed or Refractory Systemic Anaplastic Large Cell Lymphoma at ASH Annual Meeting investment picks
2014/12/6
Seattle Genetics, Inc. (Nasdaq: SGEN) and Takeda Pharmaceutical Company Limited (TSE:4502) today reported data demonstrating that Hodgkin lymphoma (HL) patients at risk of relapse following an autologous stem cell transplant (ASCT) who received ADCETRIS (brentuximab vedotin) as consolidation therapy immediately after ASCT had significant improvement in progression-free survival (PFS) compared to patients who received placebo (median of 43 months versus 24 months, respectively; hazard ratio=0.57; p-value=0.001). The data from the AETHERA trial were featured at the 56th American Society of Hematology (ASH) Annual Meeting press program today and will be presented in an oral session on December 8, 2014.
Sign-up for Seattle Genetics and Takeda Report Phase 3 AETHERA Clinical Trial Data from ADCETRIS® (Brentuximab Vedotin) in Post-Transplant Hodgkin Lymphoma Patients at Risk of Relapse at ASH Annual Meeting investment picks
2014/12/8
Seattle Genetics, Inc. (Nasdaq: SGEN) today highlighted multiple ADCETRIS (brentuximab vedotin) data presentations in frontline and salvage Hodgkin lymphoma (HL) at the 56 th American Society of Hematology (ASH) Annual Meeting and Exposition taking place in San Francisco, CA, December 6-9, 2014.
Sign-up for Seattle Genetics Highlights Multiple ADCETRIS® (Brentuximab Vedotin) Data Presentations in Frontline and Salvage Hodgkin Lymphoma at ASH Annual Meeting investment picks
2014/12/18
Seattle Genetics, Inc. (Nasdaq: SGEN) today announced initiation of a phase 1b clinical trial of SGN-CD33A in combination with standard of care chemotherapy, including cytarabine and daunorubicin, for patients with newly diagnosed acute myeloid leukemia (AML). The trial will also evaluate SGN-CD33A in the consolidation setting for AML, both in combination with cytarabine and as a single-agent maintenance regimen.
Sign-up for Seattle Genetics Initiates Phase 1b Trial of SGN-CD33A in Combination with Frontline Standard of Care and as Consolidation Therapy for Acute Myeloid Leukemia investment picks
2014/12/6
Seattle Genetics, Inc. (Nasdaq: SGEN) today presented data from two ongoing phase 1 clinical trials evaluating SGN-CD19A, an antibody-drug conjugate (ADC) in development for the treatment of B-cell malignancies, including non-Hodgkin lymphoma (NHL) and acute lymphoblastic leukemia (ALL), at the 56 th American Society of Hematology (ASH) Annual Meeting and Exposition taking place in San Francisco, CA December 6-9, 2014.
Sign-up for Seattle Genetics Presents Data from SGN-CD19A Antibody-Drug Conjugate at ASH Annual Meeting investment picks
2015/2/10
Seattle Genetics, Inc. (Nasdaq: SGEN) today reported financial results for the fourth quarter and year ended December 31, 2014.
Sign-up for Seattle Genetics Reports Fourth Quarter and Year 2014 Financial Results investment picks
2015/2/18
Seattle Genetics, Inc. (Nasdaq: SGEN) announced today that it has submitted a supplemental Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) based on data from the phase 3 AETHERA trial of ADCETRIS (brentuximab vedotin) as consolidation therapy immediately following an autologous stem cell transplant (ASCT) in Hodgkin lymphoma (HL) patients at high risk of relapse.
Sign-up for Seattle Genetics Submits Supplemental BLA to FDA for Phase 3 AETHERA Trial of ADCETRIS® (Brentuximab Vedotin) in Post-Transplant Hodgkin Lymphoma Patients at High Risk of Relapse investment picks
2015/1/21
Seattle Genetics, Inc. (NASDAQ:SGEN) announced today that it will report its fourth quarter and year 2014 financial results on Tuesday, February 10, after the close of financial markets.
Sign-up for Seattle Genetics to Host Conference Call and Webcast Discussion of Fourth Quarter and Year 2014 Financial Results on February 10, 2015 investment picks
2015/2/5
Seattle Genetics, Inc. (NASDAQ:SGEN) announced today that Clay B.
Sign-up for Seattle Genetics to Present at Leerink Global Healthcare Conference investment picks
2015/1/6
Seattle Genetics, Inc. (NASDAQ:SGEN) announced today that Clay B.
Sign-up for Seattle Genetics to Present at the J.P. Morgan Healthcare Conference investment picks
2014/12/11
By Maria Armental SeaWorld Entertainment Inc. said Jim Atchison will depart as chief executive, and the theme-park operator unveiled a restructuring plan that comes as it has faced controversy over its treatment of killer whales.
Sign-up for SeaWorld CEO to depart as theme-park operator plans restructuring investment picks
2014/12/16
- Program Start Date Accelerated to December 17, 2014 - - Authorizes Repurchases of Up to $15 Million for Remainder of Calendar Year 2014 - ORLANDO, Fla.
Sign-up for SeaWorld Entertainment, Inc. Announces Amendment of Existing Share Repurchase Program investment picks
2014/12/11
- Jim Atchison Becomes Vice Chairman; Board Launches Search for Permanent CEO - - Two New Independent Directors Appointed to Board - ORLANDO, Fla.
Sign-up for SeaWorld Entertainment, Inc. Announces David D'Alessandro Named Interim CEO investment picks
2015/2/6
ORLANDO, Fla.
Sign-up for Seaworld Entertainment, Inc. Announces Operational Management Changes investment picks
2015/1/5
ORLANDO, Fla.
Sign-up for SeaWorld Entertainment, Inc. Announces Quarterly Dividend investment picks
2014/12/16
Baby Animals, Big Cats, Kids Network, Penguins and Polar Bears will each be available for free download in the App Store.
Sign-up for SeaWorld® Kids Explores Nature With Five New, Fun Mobile Apps investment picks
2015/1/29
By Anna Molin STOCKHOLM--Skandinaviska Enskilda Banken AB (SEB-A.SK) Thursday set out new capital targets, raised its dividend and reported a 35% rise in fourth quarter net profit, driven by higher fee and commission income and lower credit losses.
Sign-up for SEB Posts Rising 4Q Profit, Sets New Capital Targets investment picks
2015/1/29
STOCKHOLM--Skandinaviska Enskilda Banken AB (SEB-A.SK) Thursday set out new capital targets, raised its dividend and reported a 35% rise in fourth quarter net profit, driven by higher fee and commission income and lower credit losses.
Sign-up for SEB Sets New Capital Targets as Profits Rise investment picks
2015/1/28
By Gregory J.
Sign-up for SEC allows marijuana dealer to register stock investment picks
2015/1/13
The Securities and Exchange Commission announced the members of its Equity Market Structure Advisory Committee on Tuesday.
Sign-up for SEC announces members of new market structure committee investment picks
2015/1/15
By Steve Goldstein, MarketWatch WASHINGTON (MarketWatch) -- The Securities and Exchange Commission on Thursday announced its third case in four days over alleged high-frequency trading abuses, this time charging UBS with not disclosing an order type that allowed some traders to jump ahead of others.
Sign-up for SEC brings third high-frequency trading case in four days investment picks
2014/12/23
A Santa Monica-based stock promoter has been charged with fraudulently raising nearly $3.5 million from investors to purchase Facebook (FB) and Twitter (TWTR) stocks before their initial public offerings.
Sign-up for SEC charges California stock promoter for defrauding investors for Facebook and Twitter shares investment picks
2015/2/5
By Angela Chen The Securities and Exchange Commission has charged four people, including a former analyst at Barclays Capital, with participating in insider trading that generated nearly $750,000 in illegal profits.
Sign-up for SEC Charges Four in Silicon Valley Insider Trading Ring investment picks
2014/12/15
A Massachusetts-based scientific instruments manufacturer has been charged with providing related travel expenses to Chinese government officials.
Sign-up for SEC charges scientific instrument company with paying Chinese officials investment picks
2015/2/5
HOUSTON, Feb.
Sign-up for SEC Closes Inquiry of LINN Energy investment picks
2014/12/15
By Maria Armental The Securities and Exchange Commission on Monday moved to dismiss insider-trading charges against a man accused of profiting from privileged information tied to Herbalife Ltd.
Sign-up for SEC files to drop insider-trading case tied to Herbalife investment picks
2014/12/8
The Securities and Exchange Commission is looking to suspend the rating of commercial mortgage bonds by McGraw Hill Financial Inc.'s (MHFI) Standard & Poor's unit, according to Bloomberg News Monday.
Sign-up for SEC looking to block S&P commercial mortgage bond rating: report investment picks
2015/2/11
By Liz Hoffman and David Benoit The Securities and Exchange Commission has waded into a dispute between petroleum refiner CVR Energy Inc. and some of the biggest names in merger advice.
Sign-up for SEC Probes CVR Disclosure During Takeover--Update 1 investment picks
Go Premium!
Exclusive Premium Member Benefits
Get the best thinking of 150+ disciplined
objective, experienced analysts-dedicated to
specific industries and securities.
+2,500 Analyst Reports
Wide Moat Screener for Stocks
Medalist Screener for Funds
Premium Portfolio Manager with X-Ray & Monitor
Premium eNewsletters
Morningstar Basic Benefits (All)
Sign up now - No charge for the first 14 days
Articles From: Seattle Genetics and Bristol-Myers Squibb Announce Clinical Collaboration to Evaluate Combination of Adcetris® (Brentuximab Vedotin) and Opdivo® (Nivolumab) in Hematologic Malignancies to SEC Probes CVR Disclosure During Takeover--Update 1
Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol |  Title Star Rating |  Category |  Total Assets |  Top Holdings |  Top Sectors |  Symbol |  Name Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol / Ticker |  Title Star Rating |  Category |  Total Assets |  Symbol / Ticker |  Name Title |  Date |  Author |  Collection |  Popularity |  Interest Title |  Date |  Company |  Symbol |  Interest |  Popularity Title |  Date |  Company |  Symbol |  Interest |  Popularity Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Name |  Ticker |  Popularity |  Our Choices |  Most Recent